Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
It’s becoming a daunting task to follow the field given the rapid-fire release of study results and the many recent submissions of new direct-acting antiviral (DAA) drugs. All will be given as cocktails, with or without interferon or ribavirin, and for various durations depending on genotype (GT) and other factors. How Continue reading Snapshot: HCV Drugs in Development
The development history of glycopeptide drugs is anything but normal. Daptomycin (Cubicin®) was abandoned by Lilly but resurrected by Francis Tally at Cubist by adjusting the dosing schedule to once daily and careful uptitration. The drug did superbly in a landmark endocarditis trial and everything looked rosy. Then we learned Continue reading Here They Are: Dalbavancin and Oritavancin – The New Long-Acting Lipoglycopeptides
The website “ClinicalTrials.gov” has become the first stop for many of us who need to check on trial activity of a particular drug. All larger human Phase 2 – 4 trials are listed there in quite some detail. While companies sometimes shy away from publishing full entry criteria or primary Continue reading And the Results are …Pending